Paul Whitney

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Parallel Private Equity LLP (Parallel Private Equity) is a private equity subsidiary of Parallel Private Equity Holdings Ltd. founded in 1997. The firm is headquartered in London.

Parallel Private Equity LLP (Parallel Private Equity) is a private equity subsidiary of Parallel Private Equity Holdings Ltd. founded in 1997. The firm is headquartered in London.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Parallel Private Equity LLP (Parallel Private Equity) is a private equity subsidiary of Parallel Private Equity Holdings Ltd. founded in 1997. The firm is headquartered in London.

3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.

Parallel Private Equity LLP (Parallel Private Equity) is a private equity subsidiary of Parallel Private Equity Holdings Ltd. founded in 1997. The firm is headquartered in London.

Phytopharm Plc is a development stage pharmaceutical company, engaged in developing novel treatments targeting diseases with high levels of unmet need. Its products include Cogane and Myogane, used in therapy for neurodegenerative diseases including Parkinson's disease, amyotrophic lateral sclerosis and glaucoma. Phytopharm was founded on November 28, 1995 and is headquartered in Huntingdon, the United Kingdom.